Signals
Migraine Prevention Gets a Wider Door
Ipsen’s Dysport programme has reported positive Phase III topline results in both episodic and chronic migraine. The signal is strong, but patients still need the full data, regulatory review and access routes that do not turn prevention into a privilege.
A new Lp(a) threshold could reshape cardiovascular risk assessment
The next cardiometabolic battleground is ultra-processed food
ADA 2026 findings show diabetes drugs are no longer just chasing glucose
Oral SERDs Face the Hard Test: Where Do They Actually Fit?
Prostate Cancer Value Starts Counting Cognition
The ASCO Drug Race Still Runs Through Genomic Testing
Alzheimer’s Blood Testing Moves the Disease Clock Earlier
Physical activity continues to strengthen its case as a cross-disease prevention strategy
The Air We Breathe May Be Shaping the Future Burden of Blindness
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.